Adult-onset Coats’ disease: a review

In 1908, George Coats published a paper about a rare form of outer retinopathy with massive exudation. Until today, the causes of the Coats’ disease (CD) has not been revealed and there is no generally accepted model of its pathogenesis. It was hypothesized that the condition could be caused by an infectious process or an inflammatory reaction, but there is no consensus about that. Genetic determinants of CD have not been identified, either. A histological examination of CD revealed “cholesterol fissures”, subretinal exudate, massive gliosis, retinal disorganization, vasodilation and hyalinization, diffuse thickening of retinal capillaries and areas of complete absence of pericytes and vascular endothelium, as well as inflammatory infiltrates. The main component of subretinal exudate is intense cell reaction of the macrophages. A study of the cytokine profile showed an increased concentration of VEGF in the subretinal fluid, the level of IL-6 was significantly higher in adult patients and correlated with the degree of exudative retinal detachment. In the eye fundus of CD patients, vascular telangiectasias followed by exudate deposition in these areas have been revealed. Complications of CD include vasoproliferative tumors, neovascular glaucoma, intraretinal and intraocular hemorrhages, vitreous fibrosis, traction retinal detachment, anterior chamber cholesterolosis. CD treatment includes laser coagulation, cryotherapy, intravitreal administration of glucocorticosteroids and angiogenesis inhibitors. In severe forms and advanced stages of CD, vitreoretinal surgery is resorted to. Enucleation may be necessary in some cases.

1. Coats G. Forms of retinal disease with massive exudation. Roy London Ophthalmol Hosp Rep. 1908; 17: 440–525.

2. Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol. 2001; 131 (5): 561–71. doi: 10.1016/s0002-9394(00)00883-7

3. Morris B, Mulvihill A. A population-based study of Coats disease in the United Kingdom I: epidemiology and clinical features at diagnosis. Eye. 2010; 24: 1797–801. doi.org/10.1038/eye.2010.126

4. Shields CL, Udyaver S, Dalvin L, et al. Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center. Indian J Ophthalmol. 2019; 67 (6): 772–83. doi: 10.4103/ijo.IJO_449_19

5. Al-Qahtani AA, Almasaud JM, Ghazi NG. Clinical characteristics and treatment outcomes of coats disease in a Saudi Arabian population. Retina. 2015; 35 (10): 2091–9. doi: 10.1097/IAE.0000000000000594

6. Kang HG, Kim JD, Choi EY, et al. Clinical features and prognostic factors in 71 eyes over 20 years from patients with Coats' disease in Korea. Sci Rep. 2021; 11 (1): 6124. doi: 10.1038/s41598-021-85739-9

7. Rishi P, Rishi E, Uparkar M, et al. Coats’ disease: an Indian perspective. Indian J Ophthalmol. 2010; 58 (2): 119. doi: 10.4103/0301-4738.60081

8. Coats G. Über Retinitis exsudativa (Retinitis haemorrhagica externa). Albrecht von Graefes Archiv für Ophthalmologie. 1912; 81: 275–327.

9. Leber T. Verber ein durch yorkommen miltipler miliaraneurisi men characterisierte form von retinal-degeneration. Graefes Arch Clin Exp Ophthalmol.1912; 81: 1–14.

10. François J, Rabaey M, Evens L, de Vos E. Etude histo-pathologique d'une rétinite de Coats probablement toxoplasmique. Ophthalmologica. 1956; 132 (1): 1–12.

11. Frezzotti R, Berengo A, Guerra R, Cavalllini F. Toxoplasmic Coats’ retinitis. Am J Ophthalmol. 1965; 59: 1099–102.

12. Teplinskaya L.E., Kaliberdina A.F. Immunopathogenetic, clinical features and treatment of external exudative Coats' retinitis. Vestnik oftal’mologii. 2000; 116 (3): 28–31 (In Russ.).

13. Ghassemi F, Sabour S. Coats disease and cytomegalovirus infection. Iran J Ophthalmol. 2012; 24 (2): 75–8.

14. Ghassemi F, Shields CL, Mohebbi M, et al. Serum hypercoagulability states in Coats’ disease. Clin Ophthalmol. 2017; 11: 305–10.

15. Reese AB. Telangiectasis of the retina and Coats’ disease. American Journal of Ophthalmology. 1956; 42 (1): 1–8. doi:10.1016/0002-9394(56)90002-2

16. Lizzio R, Monfrini E, Romano S, et al. Genetic evaluation in phenotypically discordant monozygotic twins with Coats Disease. Eur J Ophthalmol. 2023; 33 (4): NP1-NP4. doi: 10.1177/11206721221107798

17. Tarkkanen A, Laatikainen L. Coat's disease: clinical, angiographic, histopathological findings and clinical management. Br J Ophthalmol. 1983 Nov; 67 (11): 766–76. doi: 10.1136/bjo.67.11.766

18. Helmi HA, Jammah A, Maktabi AM, et al. Clinicopathological correlations in enucleated globes of late-stage Coats Disease with a review of the literature. J Epidemiol Glob Health. 2022; 12 (4): 496–503. doi: 10.1007/s44197-022-00068-y

19. Senft SH, Hidayat AA, Cavender JC. Atypical presentation of Coats disease. Retina. 1994; 14 (1): 36–8. doi: 10.1097/00006982-199401000-00008

20. Tripathi R, Ashton N. Electron microscopical study of Coat’s disease. Br J Ophthalmol. 1971; 55: 289–301.

21. Lim WK, Nussenblatt RB, Chan CC. Immunopathologic features of inflammatory coats disease. Arch Ophthalmol. 2005; 123: 279–81. doi:10.1001/archopht.123.2.279

22. Kase S, Mori S, Noda K, Ishida S. Anterior proliferative vitreoretinopathy in a patient with Coats disease. Int J Ophthalmol. 2018 Feb 18; 11 (2): 343–5. doi: 10.18240/ijo.2018.02.28

23. Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol. 2007; 245 (9): 1387–8. doi:10.1007/s00417-007-0559-8

24. He YG, Wang H, Zhao, B et al. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2010 Oct; 248 (10): 1519–21. doi: 10.1007/s00417-010-1366-1

25. Zhao Q, Peng XY, Chen FH, et al. Vascular endothelial growth factor in Coats' disease. Acta Ophthalmol. 2014; 92 (3): 225–8. doi: 10.1111/aos.12158

26. Feng J, Zheng X, Li B, Jiang Y. Differences in aqueous concentrations of cytokines in paediatric and adult patients with Coats' disease. Acta Ophthalmol. 2017 Sep; 95 (6): 608–12. doi: 10.1111/aos.13151

27. Kase S, Rao NA, Yoshikawa H, et al. Expression of vascular endothelial growth factor in eyes with Coats' disease. Invest Ophthalmol Vis Sci. 2013; 54 (1): 57–62. doi: 10.1167/iovs.12-10613

28. Zhang H, Liu ZL. Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats' disease. J Ocul Pharmacol Ther. 2012 Aug; 28 (4): 397–401. doi: 10.1089/jop.2011.0168

29. Zhang J, Jiang C, Ruan L, Huang X. Associations of cytokine concentrations in aqueous humour with retinal vascular abnormalities and exudation in coats’ disease. Acta Ophthalmol. 2019; 97 (3): 319–24.

30. Liang T, Xu Y, Zhu X, et al. Aqueous humour cytokines profiles in eyes with Coats disease and the association with the severity of the disease. BMC Ophthalmol. 2020; 20 (1): 178. doi: 10.1186/s12886-020-01421-0

31. Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats disease: the 2000 Proctor Lecture. Am J Ophthalmol. 2001 May; 131 (5): 572–83. doi: 10.1016/s0002-9394(01)00896-0

32. Daruich AL, Moulin AP, Munier FL, et al. Sub-foveal nodule in Coats’ disease: toward an updated classification predicting visual prognosis. Retina. 2017; 37: 1591–8.

33. Katsnelson L.A., Forofonova T.I., Bunin А.Ya. Vascular eye diseases. Publisher: Meditsina; 1990 (In Russ.).

34. Spitznas M, Joussen F, Wessing A, Meyer-Schwickerath G. Coat's disease. An epidemiologic and Fluorescein angiographic study. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975; 195 (4): 241–50. doi: 10.1007/BF00414937

35. Lee SM, Kim KH, Kang HG. Vascular abnormalities in fellow eyes of patients with unilateral coats' disease. Sci Rep. 2023; 13 (1):19380. https://doi.org/10.1038/s41598-023-45838-1

36. Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG. Current management of Coats disease. Surv Ophthalmol. 2014; 59 (1): 30–46. doi: 10.1016/j.survophthal.2013.03.007

37. Atta HR, Watson NJ. Echographic diagnosis of advanced Coats' disease. Eye (Lond). 1992; 6 (Pt 1): 80–5. doi: 10.1038/eye.1992.16

38. Kremer I, Nissenkorn I, Ben-Sira I. Cytologic and biochemical examination of the subretinal fluid in diagnosis of Coats' disease. Acta Ophthalmol (Copenh). 1989 Jun; 67 (3): 342–6. doi: 10.1111/j.1755-3768.1989.tb01885.x

39. Shields CL, Kaliki S, Al-Dahmash S, et al. Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases. JAMA Ophthalmol. 2013 Mar; 131 (3): 328–34. doi: 10.1001/2013.jamaophthalmol.524

40. Shanmugam MP, Shah PN, Sagar P, Ramanjulu R, Mishra DK. Coats' disease — Prognostic factors for globe and vision salvage in children, a long-term experience. Indian J Ophthalmol. 2022 Feb; 70 (2): 483–9. doi: 10.4103/ijo.IJO_1822_21

41. Burch JV, Leveille AS, Morse PH. Icthyosis hystrix (epidermal nevus syndrome) and Coats’ disease. Am J Ophthalmol. 1980 Jan; 89 (1): 25–30. doi: 10.1016/0002-9394(80)90225-1

42. Kondra L, Cangemi FE, Pitta CG. Alport's syndrome and retinal telangiectasia. Ann Ophthalmol. 1983 Jun; 15 (6): 550–1. PMID: 6571430.

43. Genkova P, Toncheva D, Tzoneva M, Konstantinov I. Deletion of 13q12.1 in a child with Coats disease. Acta Paediatr Hung. 1986; 27 (2): 141–3. PMID: 3756013.

44. Skuta GL, France TD, Stevens TS, Laxova R. Apparent Coats' disease and pericentric inversion of chromosome 3. Am J Ophthalmol. 1987 Jul 15; 104 (1): 84–6. doi: 10.1016/0002-9394(87)90299-6

45. Newell SW, Hall BD, Anderson CW, Lim ES. Hallermann Streiff syndrome with Coats’ disease. J Pediatr Ophthalmoln Strabismus. 1994; 31: 123–5. https://doi.org/10.3928/0191-3913-19940301-16

46. Luckie AP, Hamilton AM. Adult Coats' disease in branch retinal vein occlusion. Aust N Z J Ophthalmol. 1994 Aug; 22 (3): 203–6. doi: 10.1111/j.1442-9071.1994.tb01717.x

47. Magliyah M, Alshamrani AA, Schatz P, et al. Clinical spectrum, genetic associations and management outcomes of Coats-like exudative retinal vasculopathy in autosomal recessive retinitis pigmentosa. Ophthalmic Genet. 2021 Apr; 42 (2): 178–85. doi: 10.1080/13816810.2020.1867754

48. Ghorbanian S, Jaulim A, Chatziralli IP. Diagnosis and treatment of coats' disease: a review of the literature. Ophthalmologica. 2012; 227 (4): 175–82. doi: 10.1159/000336906

49. Nucci P, Bandello F, Serafino M, Wilson ME. Selective photocoagulation in Coats' disease: ten-year follow-up. Eur J Ophthalmol. 2002 Nov-Dec; 12 (6): 501–5. PMID: 12510719.

50. Haut J, Zeghal M, Limon S. Cryothérapie de la maladie de Eales et de la maladie de Coats [Cryotherapy of Eales' disease and Coats' disease]. Bull Soc Ophtalmol Fr. 1970 Feb; 70 (2): 182–4. (In French). PMID: 5454378.

51. Budning AS, Heon E, Gallie BL. Visual prognosis of Coats' disease. J AAPOS. 1998 Dec; 2 (6): 356–9. doi: 10.1016/s1091-8531(98)90034-9

52. Ozdamar Y, Berker N, Batman C, Zilelioglu O. Vitreoretinal surgery in advanced coats disease. Retin Cases Brief Rep. 2009 Winter; 3 (1): 57–9. doi: 10.1097/ICB.0b013e318154b721

53. Othman IS, Moussa M, Bouhaimed M. Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol. 2010 May; 94 (5): 606–10. doi: 10.1136/bjo.2009.168013

54. Kumar K, Raj P, Chandnani N, Agarwal A. Intravitreal dexamethasone implant with retinal photocoagulation for adult-onset Coats' disease. Int Ophthalmol. 2019 Feb; 39 (2): 465–70. doi: 10.1007/s10792-018-0827-0

55. Saatci AO, Doruk HC, Yaman A. Intravitreal dexamethasone implant (ozurdex) in coats' disease. Case Rep Ophthalmol. 2013 Sep 21; 4 (3): 122–8. doi: 10.1159/000355363

56. Bai J, Song Z, Li G, Dong L, Zhang C. Efficacy and safety of anti-vascular endothelial growth factor drugs for coats' disease treatment: A systematic review. J Ocul Pharmacol Ther. 2023 Sep; 39 (7): 418–29. doi: 10.1089/jop.2023.0028

57. Kaul S, Uparkar M, Mody K, et al. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats' disease in children. Indian J Ophthalmol. 2010 Jan-Feb; 58 (1): 76–8. doi: 10.4103/0301-4738.58480

58. Ramasubramanian A, Shields CL. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol. 2012 Mar; 96 (3): 356–9. doi: 10.1136/bjophthalmol-2011-300141

59. Yang Q, Wei W, Shi X, Yang L. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats' disease. Acta Ophthalmol. 2016 Jun; 94 (4): 401–6. doi: 10.1111/aos.13067

60. Chen Q, Liang S, Wang X, et al. Efficacy and safety outcomes of intravitreal dexamethasone implant therapy for the treatment of adult Coats' disease. J Ophthalmol. 2020 Oct 1; 2020: 9131908. doi: 10.1155/2020/9131908